$TCRT
Alaunos Therapeutics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517151749 Filed on May 01, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $1.597M $1.597M $1.970M
YoY Change -6.06% -18.93% 629.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.780M $3.600M $3.810M
YoY Change 1.89% -5.51% -10.35%
% of Gross Profit
Research & Development $10.83M $11.97M $10.20M
YoY Change -91.62% 17.34% -86.26%
% of Gross Profit
Depreciation & Amortization $90.00K $80.00K $70.00K
YoY Change 0.0% 14.29% -41.67%
% of Gross Profit
Operating Expenses $10.83M $11.97M $10.20M
YoY Change -91.62% 17.34% -86.26%
Operating Profit -$13.01M -$13.97M -$12.04M
YoY Change -90.08% 15.99% -84.61%
Interest Expense $70.00K -$1.560M
YoY Change
% of Operating Profit
Other Income/Expense, Net $86.00K $38.00K $21.00K
YoY Change 104.76% 80.95% -625.0%
Pretax Income -$12.86M -$15.49M -$12.02M
YoY Change -90.2% 28.87% -84.64%
Income Tax
% Of Pretax Income
Net Earnings -$17.73M -$19.66M -$12.02M
YoY Change -86.49% 63.56% -84.64%
Net Earnings / Revenue -1110.02% -1230.93% -610.1%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.15 -$0.09
COMMON SHARES
Basic Shares Outstanding 132.4M shares 132.4M shares 131.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.20M $66.40M $124.8M
YoY Change -10.83% -46.79% -3.78%
Cash & Equivalents $97.19M $66.45M $124.8M
Short-Term Investments
Other Short-Term Assets $27.90M $26.20M $14.50M
YoY Change 57.63% 80.69% 1511.11%
Inventory
Prepaid Expenses
Receivables $0.00 $100.0K $1.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $125.1M $92.75M $140.4M
YoY Change -1.25% -33.93% 7.49%
LONG-TERM ASSETS
Property, Plant & Equipment $1.062M $1.124M $667.0K
YoY Change 55.72% 68.52% 56.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $493.0K $492.0K $498.0K
YoY Change 0.0% -1.2% 1.43%
Total Long-Term Assets $1.683M $1.744M $1.293M
YoY Change 29.16% 34.88% 23.73%
TOTAL ASSETS
Total Short-Term Assets $125.1M $92.75M $140.4M
Total Long-Term Assets $1.683M $1.744M $1.293M
Total Assets $126.8M $94.49M $141.7M
YoY Change -0.94% -33.31% 7.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $81.00K $226.0K $1.908M
YoY Change -96.01% -88.16% 144.93%
Accrued Expenses $9.354M $10.69M $8.582M
YoY Change 26.54% 24.53% 4.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.99M $17.46M $17.27M
YoY Change -0.29% 1.1% 64.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $40.90M $42.50M $46.60M
YoY Change -8.91% -8.8% 7666.67%
Total Long-Term Liabilities $40.90M $42.50M $46.60M
YoY Change -75.05% -8.8% 7666.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.99M $17.46M $17.27M
Total Long-Term Liabilities $40.90M $42.50M $46.60M
Total Liabilities $56.85M $59.96M $63.87M
YoY Change -68.42% -6.13% 478.26%
SHAREHOLDERS EQUITY
Retained Earnings -$686.5M -$673.6M -$504.7M
YoY Change 7.95% 33.46% 11.95%
Common Stock $622.2M $578.7M $582.5M
YoY Change 6.55% -0.66% 1.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$64.27M -$94.90M $77.81M
YoY Change
Total Liabilities & Shareholders Equity $126.8M $94.49M $141.7M
YoY Change -0.94% -33.31% 7.62%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$17.73M -$19.66M -$12.02M
YoY Change -86.49% 63.56% -84.64%
Depreciation, Depletion And Amortization $90.00K $80.00K $70.00K
YoY Change 0.0% 14.29% -41.67%
Cash From Operating Activities -$15.52M -$14.28M -$16.08M
YoY Change 2.99% -11.19% 65.43%
INVESTING ACTIVITIES
Capital Expenditures $30.00K $358.0K $157.0K
YoY Change -70.0% 128.03% 823.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$360.0K -$160.0K
YoY Change -70.0% 125.0% 700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 46.30M 30.00K 370.0K
YoY Change -7010.45% -91.89% -99.62%
NET CHANGE
Cash From Operating Activities -15.52M -14.28M -16.08M
Cash From Investing Activities -30.00K -360.0K -160.0K
Cash From Financing Activities 46.30M 30.00K 370.0K
Net Change In Cash 30.75M -14.61M -15.87M
YoY Change -294.13% -7.94% -118.27%
FREE CASH FLOW
Cash From Operating Activities -$15.52M -$14.28M -$16.08M
Capital Expenditures $30.00K $358.0K $157.0K
Free Cash Flow -$15.55M -$14.64M -$16.24M
YoY Change 2.5% -9.85% 66.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
132381670 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124846000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132381670 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1698426 shares
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132381670 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2673668 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.41
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3539669 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.10
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-673606000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Liabilities
Liabilities
59955000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94494000
CY2017Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2471000
CY2017Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
251000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
226000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
-94903000
CY2017Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2471000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
39931000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
132000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
578571000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
89000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1
NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1
-122000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
17464000
CY2017Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
162000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10687000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
92750000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1124000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5795000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66447000
CY2017Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
67000
CY2017Q1 us-gaap Assets
Assets
94494000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
492000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26236000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6295000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140717000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132376670 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132376670 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2671835 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.40
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3465335 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-657997000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Liabilities
Liabilities
58325000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106348000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
862000
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
281000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
156000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-77298000
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
862000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41528000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
580567000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
126000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15809000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
155000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9109000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
104884000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
843000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3383000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81053000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
21000
CY2016Q4 us-gaap Assets
Assets
106348000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
493000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23810000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M17D
CY2016 ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
3800000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25727662 shares
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14277000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8090 pure
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M18D
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.89
CY2017Q1 dei Trading Symbol
TradingSymbol
ZIOP
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8031 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0204 pure
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M17D
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37666 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.48
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.25
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.42
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130696400 shares
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-15487000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
358000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
117000 shares
CY2017Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1560000
CY2017Q1 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13965000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
117000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0223 pure
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5000 shares
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2017Q1 us-gaap Interest Paid
InterestPaid
0
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2024000
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19658000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
79000
CY2017Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
4171000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1597000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3595000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1577000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2426000
CY2017Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
46000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
70000
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-31000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-358000
CY2017Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4171000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2024000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
172000
CY2017Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15562000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11967000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14606000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
CY2017Q1 ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
4600000
CY2017Q1 ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
3800000
CY2017Q1 ziop Research And Development Service Agreement Aggregate Payment
ResearchAndDevelopmentServiceAgreementAggregatePayment
30000000
CY2017Q1 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
49000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4990851 shares
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16079000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7969 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7915 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0158 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.88
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130157927 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0190 pure
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
20000 shares
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
157000
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5000
CY2016Q1 us-gaap Contracts Revenue
ContractsRevenue
1969000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12040000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-12019000
CY2016Q1 us-gaap Interest Paid
InterestPaid
0
CY2016Q1 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
2000
CY2016Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21000
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12019000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2009000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3125000
CY2016Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
614000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-100000
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-91000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-157000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
72000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1969000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3810000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-324000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
365000
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
104000
CY2016Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14009000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10199000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15871000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
367000
CY2016Q1 ziop Issuance Of Common Stock In Connection With License Agreement
IssuanceOfCommonStockInConnectionWithLicenseAgreement
87000

Files In Submission

Name View Source Status
0001193125-17-151749-index-headers.html Edgar Link pending
0001193125-17-151749-index.html Edgar Link pending
0001193125-17-151749.txt Edgar Link pending
0001193125-17-151749-xbrl.zip Edgar Link pending
d382546d10q.htm Edgar Link pending
d382546dex311.htm Edgar Link pending
d382546dex312.htm Edgar Link pending
d382546dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g382546g32a64.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20170331.xml Edgar Link completed
ziop-20170331.xsd Edgar Link pending
ziop-20170331_cal.xml Edgar Link unprocessable
ziop-20170331_def.xml Edgar Link unprocessable
ziop-20170331_lab.xml Edgar Link unprocessable
ziop-20170331_pre.xml Edgar Link unprocessable